Calyx Pharma
Mumbai, India· Est.
Early‑stage Indian biotech leveraging AI‑driven small‑molecule discovery for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Early‑stage Indian biotech leveraging AI‑driven small‑molecule discovery for oncology and immunology.
Technology Platform
Proprietary AI‑driven small‑molecule discovery platform integrating computational modeling, structure‑based design, and high‑throughput screening.
Opportunities
Leverage AI‑driven discovery to accelerate oncology and immunology asset development and attract partnership or licensing deals with global pharma.
Risk Factors
Technology validation, lack of clinical data, and intense competition from well‑funded domestic and international biotech firms.
Competitive Landscape
Competes with Indian and global biotech companies; differentiation rests on its AI‑enabled discovery platform and potential for faster lead generation.